BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schirrmacher V, van Gool S, Stuecker W. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Biomedicines 2019;7:E66. [PMID: 31480379 DOI: 10.3390/biomedicines7030066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 bin Umair M, Akusa FN, Kashif H, Seerat-e-fatima, Butt F, Azhar M, Munir I, Ahmed M, Khalil W, Sharyar H, Rafique S, Shahid M, Afzal S. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. [DOI: 10.1007/s00705-022-05432-8] [Reference Citation Analysis]
2 Burman B, Pesci G, Zamarin D. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers (Basel) 2020;12:E3552. [PMID: 33260685 DOI: 10.3390/cancers12123552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
3 Javanbakht M, Tahmasebzadeh S, Cegolon L, Gholami N, Kashaki M, Nikoueinejad H, Mozafari M, Mozaffari M, Zhao S, Khafaei M, Izadi M, Fathi S, Akhavan-sigari R. Oncolytic viruses: A novel treatment strategy for breast cancer. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.11.011] [Reference Citation Analysis]
4 Fulber JPC, Kamen AA. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses 2022;14:975. [DOI: 10.3390/v14050975] [Reference Citation Analysis]
5 Alshaibi HF, Al-Shehri B, Hassan B, Al-Zahrani R, Assiss T. Modulated Electrohyperthermia: A New Hope for Cancer Patients. Biomed Res Int 2020;2020:8814878. [PMID: 33274226 DOI: 10.1155/2020/8814878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Banerjee K, Núñez FJ, Haase S, McClellan BL, Faisal SM, Carney SV, Yu J, Alghamri MS, Asad AS, Candia AJN, Varela ML, Candolfi M, Lowenstein PR, Castro MG. Current Approaches for Glioma Gene Therapy and Virotherapy. Front Mol Neurosci 2021;14:621831. [PMID: 33790740 DOI: 10.3389/fnmol.2021.621831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jadhav A, Zhao L, Liu W, Ding C, Nair V, Ramos-Onsins SE, Ferretti L. Genomic Diversity and Evolution of Quasispecies in Newcastle Disease Virus Infections. Viruses 2020;12:E1305. [PMID: 33202558 DOI: 10.3390/v12111305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 LeBlanc N, Mallette E, Zhang W. Targeted modulation of E3 ligases using engineered ubiquitin variants. FEBS J 2021;288:2143-65. [PMID: 32867007 DOI: 10.1111/febs.15536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Edwardson TGW, Levasseur MD, Tetter S, Steinauer A, Hori M, Hilvert D. Protein Cages: From Fundamentals to Advanced Applications. Chem Rev 2022. [PMID: 35394752 DOI: 10.1021/acs.chemrev.1c00877] [Reference Citation Analysis]
10 Liang Y, Tian WY, Huang JJ, Gao LX, Fan XH. MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells. Oncol Lett 2021;21:482. [PMID: 33968198 DOI: 10.3892/ol.2021.12743] [Reference Citation Analysis]
11 Stavrakaki E, Dirven CMF, Lamfers MLM. Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. Cancers (Basel) 2021;13:614. [PMID: 33557101 DOI: 10.3390/cancers13040614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sprenger T, Schirrmacher V, Stücker W, van Gool SW. Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies. Expert Rev Anticancer Ther 2020;20:639-46. [PMID: 32600076 DOI: 10.1080/14737140.2020.1785874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang W, Chen CC, Ning J. Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy. Expert Opin Biol Ther 2021;21:183-9. [PMID: 32799567 DOI: 10.1080/14712598.2020.1811848] [Reference Citation Analysis]
14 Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 2020;8:E61. [PMID: 32188078 DOI: 10.3390/biomedicines8030061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Redd Bowman KE, Lu P, Vander Mause ER, Lim CS. Advances in delivery vectors for gene therapy in liver cancer. Therapeutic Delivery 2020;11:833-50. [DOI: 10.4155/tde-2019-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Schirrmacher V, Sprenger T, Stuecker W, Van Gool SW. Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit. Biomedicines 2020;8:E237. [PMID: 32717895 DOI: 10.3390/biomedicines8080237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schirrmacher V. Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications. Biomedicines 2021;9:293. [PMID: 33805626 DOI: 10.3390/biomedicines9030293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Schirrmacher V. Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus. Biomedicines 2022;10:562. [DOI: 10.3390/biomedicines10030562] [Reference Citation Analysis]
19 Liu H, Luo H. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges. Viruses 2021;13:1082. [PMID: 34198859 DOI: 10.3390/v13061082] [Reference Citation Analysis]
20 Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Front Immunol 2021;12:721830. [PMID: 34675919 DOI: 10.3389/fimmu.2021.721830] [Reference Citation Analysis]
21 García-Romero N, Palacín-Aliana I, Esteban-Rubio S, Madurga R, Rius-Rocabert S, Carrión-Navarro J, Presa J, Cuadrado-Castano S, Sánchez-Gómez P, García-Sastre A, Nistal-Villan E, Ayuso-Sacido A. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. Cells 2020;9:E1405. [PMID: 32516884 DOI: 10.3390/cells9061405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Schirrmacher V. New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection. Biomedicines 2020;8:E55. [PMID: 32155856 DOI: 10.3390/biomedicines8030055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Schirrmacher V. Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism. Biomedicines 2020;8:E526. [PMID: 33266387 DOI: 10.3390/biomedicines8110526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wang X, Zhao X, He Z. Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy. Oncol Lett 2021;21:238. [PMID: 33664802 DOI: 10.3892/ol.2021.12499] [Reference Citation Analysis]
25 Vijayakumar G, McCroskery S, Palese P. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. J Virol 2020;94:e01677-19. [PMID: 31694938 DOI: 10.1128/JVI.01677-19] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
26 Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution. Cancer Immunol Immunother 2021;70:1393-403. [PMID: 33151369 DOI: 10.1007/s00262-020-02751-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Peters CWD, Nigim F. Immunomodulatory Arming Factors-The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules. Int J Mol Sci 2021;22:9051. [PMID: 34445759 DOI: 10.3390/ijms22169051] [Reference Citation Analysis]
28 Mohammed MS, Al-Taee MF, Al-Shammari AM. Caspase Dependent and Independent Anti-hematological Malignancy Activity of AMHA1 Attenuated Newcastle Disease Virus. Int J Mol Cell Med 2019;8:211-23. [PMID: 32489950 DOI: 10.22088/IJMCM.BUMS.8.3.211] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, Patin EC, McLaughlin M, Mansfield D, Baker G, Grove L, Pedersen M, Kyula J, Roulstone V, Wilkins A, McDonald F, Harrington K, Melcher A. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opin Biol Ther 2020;20:635-52. [PMID: 32067509 DOI: 10.1080/14712598.2020.1729351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]